The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1270
Pregabalin (Lyrica) for Fibromyalgia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Pregabalin (Lyrica – Pfizer) is the first drug approved by the FDA for management of fibromyalgia. When it was first marketed, pregabalin, which is structurally similar to gabapentin (Neurontin, and others), was approved for treatment of neuropathic pain associated with postherpetic neuralgia and diabetic peripheral neuropathy and for adjunctive treatment of partial onset seizures in adults with epilepsy.1 It has also been prescribed off-label for other types of neuropathic pain such as sciatica.

FIBROMYALGIA — A chronic disorder mainly affecting women, fibromyalgia is characterized by pain, fatigue and sleep problems. It has been treated with many different drugs, including analgesics, muscle relaxants, anticonvulsants such as gabapentin, and antidepressants; the tricyclic antidepressant amitriptyline (Elavil, and others) has probably been the best studied. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Pregabalin (Lyrica) for Fibromyalgia
Article code: 1270a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian